cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.6084/m9.figshare.3806649.v1
title: Dutch translation and validation of the readiness for interprofessional learning scale (RIPLS) in a primary healthcare context

description: <b>Background:</b> Interprofessional education and collaborative practice are gradually gaining importance in the context of growing healthcare complexity. The readiness for interprofessional learning scale (RIPLS) is a well-known scale that can identify attitudinal barriers and variance across professions, which may affect educational interventions. <b>Objectives:</b> This study aims to translate the English RIPLS into Dutch and to test its reliability and validity. <b>Methods:</b> The scale was translated and back-translated by two pairs of people independently and tested for feasibility and comprehensibility. The translated scale was used with 219 general practitioners, 238 community nurses, and 53 palliative home-care nurses. Exploratory factor analysis was used to assess construct validity. Confirmatory factor analysis was done to generate a fit model. Cronbach’s alpha was computed to evaluate internal consistency. Regression analysis was used to evaluate the effect of the RIPLS score on the level of learning through collaboration and to gauge the influence of the participants’ gender, age, previous palliative care education, type of practice and years in practice. <b>Results:</b> Confirmatory and exploratory factor analysis confirms the factor structure of the original version. The Dutch version shows good reliability (overall Cronbach’s alpha: 0.88; intraclass correlation coefficient after test-retest: 0.718 (95%CI: 0.499–0.852). The RIPLS score correlates with the amount of workplace learning during collaboration (discriminant validity: <i>P</i> <b>Conclusion:</b> The Dutch translation of the RIPLS is now ready for comparative studies.
DOI: 10.6084/m9.figshare.3806643
title: Dose-volume analysis of radiation-induced trismus in head and neck cancer patients

description: <b>Introduction:</b> Trismus is a treatment-related late side effect in patients treated for cancer in the head and neck region (HNC). The condition can have a considerable negative impact on nutrition, dental hygiene, ability to speak and quality of life. We have previously studied trismus within the frame of a randomized phase 3 study of HNC patients treated with mainly three-dimensional (3D) conformal radiotherapy (CRT) and found a strong association to mean radiation dose to the mastication muscles, especially the ipsilateral masseter muscle (<i>i</i>MAS). In the present study we have investigated trismus prevalence and risk factors in a more recent cohort of patients, treated with todays’ more updated radiation techniques. <b>Material and methods:</b> Maximal interincisal distance (MID) was measured on 139 consecutive patients. Trismus was defined as MID ≤35 mm. Patient-, disease- and treatment-specific data were retrospectively recorded. Differences between groups were analyzed and mean absorbed dose to mastication structures was evaluated. Dosimetric comparisons were made between this study and our previous results. <b>Results:</b> The prevalence of trismus was 24% at a median of 16 months after completion of radiotherapy. In bivariate analysis treatment technique (3DCRT vs. intensity modulated radiotherapy or helical tomotherapy), tumor site (oropharynx vs. other sites) and mean radiation doses to the ipsilateral lateral pterygoid muscle, the paired masseter muscles and the <i>i</i>MAS were significantly associated with MID ≤35 mm. In multivariable analysis only mean radiation dose to the <i>i</i>MAS was significantly associated to MID ≤35 mm. <b>Conclusion:</b> Mean radiation dose to the ipsilateral masseter muscle is an important risk factor for trismus development. Dose reduction to this structure during radiotherapy should have a potential to diminish the prevalence of trismus in this patient group.
DOI: 10.6084/m9.figshare.3806643.v2
title: Dose-volume analysis of radiation-induced trismus in head and neck cancer patients

description: <b>Introduction:</b> Trismus is a treatment-related late side effect in patients treated for cancer in the head and neck region (HNC). The condition can have a considerable negative impact on nutrition, dental hygiene, ability to speak and quality of life. We have previously studied trismus within the frame of a randomized phase 3 study of HNC patients treated with mainly three-dimensional (3D) conformal radiotherapy (CRT) and found a strong association to mean radiation dose to the mastication muscles, especially the ipsilateral masseter muscle (<i>i</i>MAS). In the present study we have investigated trismus prevalence and risk factors in a more recent cohort of patients, treated with todays’ more updated radiation techniques. <b>Material and methods:</b> Maximal interincisal distance (MID) was measured on 139 consecutive patients. Trismus was defined as MID ≤35 mm. Patient-, disease- and treatment-specific data were retrospectively recorded. Differences between groups were analyzed and mean absorbed dose to mastication structures was evaluated. Dosimetric comparisons were made between this study and our previous results. <b>Results:</b> The prevalence of trismus was 24% at a median of 16 months after completion of radiotherapy. In bivariate analysis treatment technique (3DCRT vs. intensity modulated radiotherapy or helical tomotherapy), tumor site (oropharynx vs. other sites) and mean radiation doses to the ipsilateral lateral pterygoid muscle, the paired masseter muscles and the <i>i</i>MAS were significantly associated with MID ≤35 mm. In multivariable analysis only mean radiation dose to the <i>i</i>MAS was significantly associated to MID ≤35 mm. <b>Conclusion:</b> Mean radiation dose to the ipsilateral masseter muscle is an important risk factor for trismus development. Dose reduction to this structure during radiotherapy should have a potential to diminish the prevalence of trismus in this patient group.
DOI: 10.6084/m9.figshare.3806643.v1
title: Dose-volume analysis of radiation-induced trismus in head and neck cancer patients

description: <b>Introduction:</b> Trismus is a treatment-related late side effect in patients treated for cancer in the head and neck region (HNC). The condition can have a considerable negative impact on nutrition, dental hygiene, ability to speak and quality of life. We have previously studied trismus within the frame of a randomized phase 3 study of HNC patients treated with mainly three-dimensional (3D) conformal radiotherapy (CRT) and found a strong association to mean radiation dose to the mastication muscles, especially the ipsilateral masseter muscle (<i>i</i>MAS). In the present study we have investigated trismus prevalence and risk factors in a more recent cohort of patients, treated with todays’ more updated radiation techniques. <b>Material and methods:</b> Maximal interincisal distance (MID) was measured on 139 consecutive patients. Trismus was defined as MID ≤35 mm. Patient-, disease- and treatment-specific data were retrospectively recorded. Differences between groups were analyzed and mean absorbed dose to mastication structures was evaluated. Dosimetric comparisons were made between this study and our previous results. <b>Results:</b> The prevalence of trismus was 24% at a median of 16 months after completion of radiotherapy. In bivariate analysis treatment technique (3DCRT vs. intensity modulated radiotherapy or helical tomotherapy), tumor site (oropharynx vs. other sites) and mean radiation doses to the ipsilateral lateral pterygoid muscle, the paired masseter muscles and the <i>i</i>MAS were significantly associated with MID ≤35 mm. In multivariable analysis only mean radiation dose to the <i>i</i>MAS was significantly associated to MID ≤35 mm. <b>Conclusion:</b> Mean radiation dose to the ipsilateral masseter muscle is an important risk factor for trismus development. Dose reduction to this structure during radiotherapy should have a potential to diminish the prevalence of trismus in this patient group.
DOI: 10.6084/m9.figshare.3806616
title: Supporting conservation: the roles of flagship species and identifiable victims

description: We experimentally investigated how (i) identifiable versus statistical beneficiaries and (ii) flagship versus non-flagship species affected donations to a conservation charity. <br>All data were collected in March 2016 using the online labour market, Amazon Mechanical Turk. All respondents were US-based, approval rate &gt; 75%, no of HITS completed &gt; 0. <br><br>All subjects were paid a show-up fee of $0.40 and presented with information about the effects of climate change on various species. They were then given a $0.50 endowment and the opportunity to donate as much or as little of this endowment as they wished to WWF, a charity working to mitigate the effects of climate change on each species. <br>Subjects were also required to answer five questions to measure attitudes towards climate change (two questions), the sense of responsibility felt towards other species (two questions); and the extent to which individuals would be willing to modify their behaviour to reduce negative climate impacts (one question).<br><br>Respondent data and R code for analysis is available.
DOI: 10.6084/m9.figshare.3806616.v1
title: data.xlsx

description: We experimentally investigated how (i) identifiable versus statistical beneficiaries and (ii) flagship versus non-flagship species affected donations to a conservation charity. <br>All data were collected in March 2016 using the online labour market, Amazon Mechanical Turk. All respondents were US-based, approval rate &gt; 75%, no of HITS completed &gt; 0. <br><br>All subjects were paid a show-up fee of $0.40 and presented with information about the effects of climate change on various species. They were then given a $0.50 endowment and the opportunity to donate as much or as little of this endowment as they wished to WWF, a charity working to mitigate the effects of climate change on each species. <br>Subjects were also required to answer five questions to measure attitudes towards climate change (two questions), the sense of responsibility felt towards other species (two questions); and the extent to which individuals would be willing to modify their behaviour to reduce negative climate impacts (one question).<br><br>Respondent data and R code for analysis is available.
DOI: 10.6084/m9.figshare.3806613
title: PowerPoint Slides for: New Onset Hypertension Linked to Generic Cyclosporine Substitution in Post-Renal Transplant Patient

description: This is case report and review of the literature focused on generic substitutions of cyclosporine and its consequences. The pharmacokinetics and pharmacodynamics of the generic substitutions are clear different than the parent compound Sandimmune and can lead to different outcomes, as was the case in this report. A detailed accounting of the patients history led to the discovery of the problem and sorting back to a the branded drug supported the hypothesis.
DOI: 10.6084/m9.figshare.3806601
title: PowerPoint Slides for: Severity of Gastric Mucosal Atrophy Is the Major Determinant of Plasma Ghrelin Level in Hemodialysis Patients

description: <i>Background:</i> Ghrelin, an orexigenic hormone, has multiple favorable functions including protein anabolism enhancement, anti-inflammatory actions, and cardiovascular protection. A low plasma ghrelin level is associated with increased mortality in patients treated with hemodialysis (HD). However, it is unclear whether the plasma ghrelin level in HD patients correlates with the severity of gastric mucosal atrophy and <i>Helicobacter pylori</i> status. <i>Methods:</i> Seventy-eight maintenance HD patients and 51 non-dialysis patients with chronic kidney disease were evaluated for severity of gastric mucosal atrophy by gastroduodenoscopy and for <i>H. pylori</i> status using an anti-<i>H. pylori</i>-antibody and rapid urease test. Plasma acyl and des-acyl ghrelin levels were measured and their associations with relevant clinical parameters were investigated. <i>Results:</i> Des-acyl ghrelin level in HD patients was significantly higher than that in patients with kidney function preserved. Although acyl and des-acyl ghrelin levels were similar between current <i>H. pylori </i>positive and negative HD patients, both levels decreased significantly with the progress of endoscopic gastric mucosal atrophy in HD patients. Serum pepsinogen (PG) I level and PG I/II ratio decreased significantly according to the severity of atrophy in HD patients and positively significantly correlated with both ghrelin levels. Multiple regression analysis showed significant positive correlations between acyl ghrelin and PG I levels (β = 0.738, p &lt; 0.001) and significant negative correlations between ghrelin and age, albumin, and creatinine levels. <i>Conclusions:</i> Gastric atrophy is the major determinant of ghrelin level in HD patients. Management practices, such as <i>H. pylori</i> eradication, before advanced atrophy may be required to prevent the decrease of ghrelin levels and improve the prognosis of HD patients.
DOI: 10.6084/m9.figshare.3806613.v1
title: PowerPoint Slides for: New Onset Hypertension Linked to Generic Cyclosporine Substitution in Post-Renal Transplant Patient

description: This is case report and review of the literature focused on generic substitutions of cyclosporine and its consequences. The pharmacokinetics and pharmacodynamics of the generic substitutions are clear different than the parent compound Sandimmune and can lead to different outcomes, as was the case in this report. A detailed accounting of the patients history led to the discovery of the problem and sorting back to a the branded drug supported the hypothesis.
DOI: 10.6084/m9.figshare.3806601.v1
title: PowerPoint Slides for: Severity of Gastric Mucosal Atrophy Is the Major Determinant of Plasma Ghrelin Level in Hemodialysis Patients

description: <i>Background:</i> Ghrelin, an orexigenic hormone, has multiple favorable functions including protein anabolism enhancement, anti-inflammatory actions, and cardiovascular protection. A low plasma ghrelin level is associated with increased mortality in patients treated with hemodialysis (HD). However, it is unclear whether the plasma ghrelin level in HD patients correlates with the severity of gastric mucosal atrophy and <i>Helicobacter pylori</i> status. <i>Methods:</i> Seventy-eight maintenance HD patients and 51 non-dialysis patients with chronic kidney disease were evaluated for severity of gastric mucosal atrophy by gastroduodenoscopy and for <i>H. pylori</i> status using an anti-<i>H. pylori</i>-antibody and rapid urease test. Plasma acyl and des-acyl ghrelin levels were measured and their associations with relevant clinical parameters were investigated. <i>Results:</i> Des-acyl ghrelin level in HD patients was significantly higher than that in patients with kidney function preserved. Although acyl and des-acyl ghrelin levels were similar between current <i>H. pylori </i>positive and negative HD patients, both levels decreased significantly with the progress of endoscopic gastric mucosal atrophy in HD patients. Serum pepsinogen (PG) I level and PG I/II ratio decreased significantly according to the severity of atrophy in HD patients and positively significantly correlated with both ghrelin levels. Multiple regression analysis showed significant positive correlations between acyl ghrelin and PG I levels (β = 0.738, p &lt; 0.001) and significant negative correlations between ghrelin and age, albumin, and creatinine levels. <i>Conclusions:</i> Gastric atrophy is the major determinant of ghrelin level in HD patients. Management practices, such as <i>H. pylori</i> eradication, before advanced atrophy may be required to prevent the decrease of ghrelin levels and improve the prognosis of HD patients.
DOI: 10.6084/m9.figshare.3806595
title: PowerPoint Slides for: Dose-Titrated Vasopressin V2 Receptor Antagonist Improves Renoprotection in a Mouse Model for Autosomal Dominant Polycystic Kidney Disease

description: <i>Background:</i> In autosomal dominant polycystic kidney disease, renoprotective treatment with a vasopressin V2 receptor antagonist (V2RA) is given in a fixed dose (FD). Disease progression and drug habituation could diminish treatment efficacy. We investigated whether the renoprotective effect of the V2RA can be improved by dose titration of the V2RA aiming to maintain aquaresis at a high level. <i>Methods:</i> The V2RA OPC-31260 was administered to <i>Pkd1</i>-deletion mice in an FD (0.1%) or in a titrated dose (TD, up to 0.8% when drinking volume dropped). Total kidney weight (TKW) and cyst ratio were investigated and compared to non-treated <i>Pkd1</i>-deletion mice. Treatment was started early or late (21 or 42 days postnatal). <i>Results:</i> Water intake was significantly higher throughout the experiment in the TD compared to the FD group. FD treatment that was initiated early reduced TKW and cyst ratio but lost its renoprotective effect later during the experiment. In contrast, TD treatment was able to maintain the renoprotective effect. TD treatment, however, was also associated with a higher early termination rate in comparison with FD treatment. Late start of treatment (FD or TD) did not show a renoprotective effect. <i>Conclusions:</i> Titration of a V2RA aimed to maintain aquaresis at a high level showed a better renoprotective effect compared to FD administration. However, this treatment regimen was poorly tolerated and did not overcome treatment unresponsiveness when started later in the disease.
DOI: 10.6084/m9.figshare.3806595.v1
title: PowerPoint Slides for: Dose-Titrated Vasopressin V2 Receptor Antagonist Improves Renoprotection in a Mouse Model for Autosomal Dominant Polycystic Kidney Disease

description: <i>Background:</i> In autosomal dominant polycystic kidney disease, renoprotective treatment with a vasopressin V2 receptor antagonist (V2RA) is given in a fixed dose (FD). Disease progression and drug habituation could diminish treatment efficacy. We investigated whether the renoprotective effect of the V2RA can be improved by dose titration of the V2RA aiming to maintain aquaresis at a high level. <i>Methods:</i> The V2RA OPC-31260 was administered to <i>Pkd1</i>-deletion mice in an FD (0.1%) or in a titrated dose (TD, up to 0.8% when drinking volume dropped). Total kidney weight (TKW) and cyst ratio were investigated and compared to non-treated <i>Pkd1</i>-deletion mice. Treatment was started early or late (21 or 42 days postnatal). <i>Results:</i> Water intake was significantly higher throughout the experiment in the TD compared to the FD group. FD treatment that was initiated early reduced TKW and cyst ratio but lost its renoprotective effect later during the experiment. In contrast, TD treatment was able to maintain the renoprotective effect. TD treatment, however, was also associated with a higher early termination rate in comparison with FD treatment. Late start of treatment (FD or TD) did not show a renoprotective effect. <i>Conclusions:</i> Titration of a V2RA aimed to maintain aquaresis at a high level showed a better renoprotective effect compared to FD administration. However, this treatment regimen was poorly tolerated and did not overcome treatment unresponsiveness when started later in the disease.
DOI: 10.6084/m9.figshare.3806544
title: Supplementary Material for: The Acute Cystitis Symptom Score for Patient-Reported Outcome Assessment

description: <i>Objectives:</i> The Acute Cystitis Symptom Score (ACSS) was developed as a self-reporting questionnaire for clinical diagnosis of acute uncomplicated cystitis (AUC) and symptomatic changes in female patients. The aim of the present study was to assess the utility of the different domains of ACSS including the ‘dynamics' domain after therapy. The applicability of these domains in assessing changes in symptoms, as a function of time, in this population was investigated. <i>Materials and Methods:</i>During the validation process of the ACSS in Uzbek and Russian languages, a subgroup of patients (n = 63) returned after therapy and filled in part B of ACSS. Descriptive statistics were used, where suitable. <i>Results:</i> The reduction of typical symptoms and quality of life (QoL) assessment between first and follow-up visit correlated significantly with answers in the ‘dynamics' domain. Success/cure and non-success/failure could be clearly differentiated by the scores obtained in ‘typical' and ‘QoL' domains. <i>Conclusion:</i> The ACSS has proven to be a useful instrument to clinically diagnose AUC in women. It is also a suitable instrument for patient-reported outcome assessment, with applicability in both daily practice and in clinical studies. Slight modifications in the ‘dynamics' domain will even increase the applicability.
DOI: 10.6084/m9.figshare.3806538
title: Supplementary Material for: Serum Potassium Levels and Mortality in Hemodialysis Patients: A Retrospective Cohort Study

description: <i>Background:</i> Hyperkalemia is common in patients receiving maintenance hemodialysis. However, few studies have examined the association between serum potassium level and mortality. <i>Methods:</i> This study used annual cohorts of hemodialysis patients during 2007-2010. To determine hyperkalemia prevalence, monthly hyperkalemia was defined as serum potassium level ≥5.5 mEq/l; prevalence was calculated as a ratio of hyperkalemia episodes to follow-up time, reported separately by long and short interdialytic interval. To determine the impact of hyperkalemia on mortality, patients in the 2010 cohort were followed from first potassium measurement until death or a censoring event; hyperkalemia was defined, sequentially, by potassium levels 5.5-6.0 mEq/l at 0.1 mEq/l intervals. Time-dependent Cox proportional hazards modeling was used to estimate the association between hyperkalemia and mortality. <i>Results:</i> The 4 annual cohorts ranged from 28,774 to 36,888 patients. Mean age was approximately 63 years, about 56% were men, 51% were white and 44% had end-stage renal disease caused by diabetes. Hyperkalemia prevalence was consistently estimated at 16.3-16.8 events per 100 patient-months. Prevalence on the day after the long interdialytic interval was 2.0-2.4 times as high as on the day after the short interval. Hyperkalemia, when defined as serum potassium ≥5.7 mEq/l, was associated with all-cause mortality (adjusted hazards ratio (AHR) 1.13, 95% CI 1.01-1.28, p = 0.037, vs. &lt;5.7 mEq/l) after adjustment. AHRs increased progressively as the hyperkalemia threshold increased, reaching 1.37 (95% CI 1.16-1.62, p &lt; 0.0001) for ≥6.0 mEq/l. <i>Conclusions:</i> The long interdialytic interval was associated with increased likelihood of hyperkalemia. Hyperkalemia was associated with all-cause mortality beginning at serum potassium ≥5.7 mEq/l; mortality risk estimates increased ordinally through ≥6.0 mEq/l, suggesting a threshold at which serum potassium becomes substantially more dangerous.